Uses of Ranidin: - Gastroesophageal reflux disease (Acid reflux) - Peptic ulcer disease Dyspepsia, H. pylori infection, Benign gastric and duodenal ulceration, GERD, Acid aspiration during general anesth, Prophylaxis during NSAID treatment, Stress ulceration of upper GI, Zollinger-Ellison syndrome Porphyria.

H2 receptor antagonist

Ranitidine competitively blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. It does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.

How to use Ranitidine: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Ranitidine may be taken with or without food, but it is better to take it at a fixed time. Administration: May be taken with or without food. IV Administration Direct injection: 50 mg diluted to ?20 mL with compatible IV infusion fluid and given over ?5 minutes (4 mL/min) Intermittent infusion: 50 mg added to ?100 mL of compatible IV solution and infused over 15-20 minutes Continuous infusion: 150 mg diluted in 250 mL of IV fluid and infused at 6.25 mg/hr for 24 hours Adult Dose: Oral Benign gastric and duodenal ulceration Adult: Initially, 300 mg daily at bedtime or 150 mg bid for 4-8 wk; 300 mg bid for 4 wk may be used in duodenal ulcer to improved healing. Maintenance: 150 mg daily at bedtime. Max: 300 mg bid. Hypersecretory conditions Adult: Initially, 150 mg bid or tid and increased if needed. Max: 6 g daily. Gastro-oesophageal reflux disease Adult: 150 mg bid or 300 mg at bedtime for up to 8 wk, may increase to 150 mg 4 times daily for 12 wk in severe cases. Dyspepsia Adult: Chronic episodic: 150 mg bid for up to 6 wk. Short-term symptomatic relief: 75 mg repeated if necessary up to 4 doses daily. Max duration: 2 wk of continuous use at one time. Erosive oesophagitis Adult: 150 mg 4 times daily. Maintenance: 150 mg bid. NSAID-associated ulceration Adult: 150 mg bid or 300 mg at bedtime for 8-12 wk. For prevention of NSAID-associated ulceration: 150 mg bid. Hepatic impairment: Dosage adjustment not necessary Child Dose: Oral Benign gastric and duodenal ulceration Child: 1 mth to 16 yr 4-8 mg/kg daily in 2 divided doses. Max: 300 mg/day. Treatment duration: 4-8 wk. Maintenance: 2-4 mg/kg once daily. Max: 150 mg/day. Gastro-oesophageal reflux disease Child: 1 mth to 16 yr 5-10 mg/kg daily in 2 divided doses. Max: 300 mg/day. Erosive oesophagitis Child: 1 mth to 16 yr 5-10 mg/kg daily in 2 divided doses. Max: 600 mg/day. Renal Dose: Oral: CrCl Dosage <50 150 mg daily at bedtime, adjust dose cautiously if necessary.Parenteral: Individual doses may be reduced to 25 mg.

Delayed absorption and increased peak serum concentration w/ propantheline bromide. Ranitidine minimally inhibits hepatic metabolism of coumarin anticoagulants, theophylline, diazepam and propanolol. May alter absorption of pH-dependent drugs (e.g. ketoconazole, midazolam, glipizide). May reduce bioavailability w/ antacids.

Porphyria.

Common - Sleepiness - Headache - Tiredness - Constipation - Diarrhea 1-10% Headache (3%) <1% Abdominal pain,Agitation,Alopecia,Confusion,Constipation,Diarrhea,Dizziness,Hypersensitivity reaction,Nausea,Vomiting Frequency Not Defined Anemia,Necrotizing enterocolitis in fetus or newborn,Pancreatitis (rare),Thrombocytopenia (rare),Pancytopenia (rare),Agranulocytosis (rare),Acquired immune hemolytic anemia (rare),Arthralgia (rare),Myalgia (rare) Potentially Fatal: Anaphylaxis, hypersensitivity reactions.

Pregnancy: Ranitidine crosses the placenta. But there is no evidence of impaired fertility or harm to the foetus due to Ranitidine. Like other drugs, Ranitidine should only be used during pregnancy if considered essential.Lactation: Ranitidine is excreted in human breast milk. Caution should be exercised when the drug is administered to a nursing mother.

Precaution: Possibility of malignancy should be excluded prior to therapy as the drug may mask symptoms and delay diagnosis of gastric malignancy. Patients w/ difficulty in swallowing. Renal and hepatic impairment. Pregnancy and lactation. Lactation: Drug crosses into breast milk; discontinue drug, use caution

Ranitidine is very specific in action and accordingly no particular problems are expected following overdosage with the drug. Symptomatic and supportive therapy should be given as appropriate. If required, the drug may be removed from the plasma by haemodiaiysis.

Store in a cool and dry place. protect from light.

Ranitidine competitively blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. It does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.